Peter Maslak
Overview
Explore the profile of Peter Maslak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
5331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herr M, Balderman S, Wallace P, Zhang Y, Tario Jr J, Buxbaum N, et al.
Transplant Cell Ther
. 2024 May;
30(8):808.e1-808.e13.
PMID: 38801976
Haploidentical (Haplo) allogeneic HCTs (alloHCT) have been used more frequently over the last decade as survival is similar to HLA-matched related donor (MRD) alloHCTs. We aimed to identify donor and...
2.
Melica G, Preston E, Palazzo M, Seier K, Malard F, Cho C, et al.
Bone Marrow Transplant
. 2024 Feb;
59(5):625-629.
PMID: 38351281
Myeloablative T cell depleted (CD34-selected) hematopoietic cell transplantation (HCT) is associated with less acute and chronic graft versus host disease (GVHD). We aimed to examine vaccine responses in relation to...
3.
Miltiadous O, Waters N, Andrlova H, Dai A, Nguyen C, Burgos da Silva M, et al.
Blood
. 2022 Jan;
139(18):2758-2769.
PMID: 35061893
Low intestinal microbial diversity is associated with poor outcomes after allogeneic hematopoietic cell transplantation (HCT). Using 16S rRNA sequencing of 2067 stool samples and flow cytometry data from 2370 peripheral...
4.
Lee C, Shah M, Hoyos D, Solovyov A, Douglas M, Taur Y, et al.
Cancer Discov
. 2021 Nov;
12(1):62-73.
PMID: 34753749
Coronavirus disease 2019 (COVID-19) infection results in both acute mortality and persistent and/or recurrent disease in patients with hematologic malignancies, but the drivers of persistent infection in this population are...
5.
Jacob R, Flynn J, Devlin S, Maloy M, Giralt S, Maslak P, et al.
Transplant Cell Ther
. 2021 May;
27(8):697.e1-697.e5.
PMID: 33991721
As a result of the COVID-19 pandemic, most centers performing allogeneic hematopoietic cell transplantation (allo-HCT) have switched to the use of cryopreserved grafts. Previous investigators have suggested that cryopreserved allografts...
6.
Geyer M, Ritchie E, Rao A, Vemuri S, Flynn J, Hsu M, et al.
Haematologica
. 2020 Oct;
106(8):2086-2094.
PMID: 33054114
Administration of pediatric-inspired chemotherapy to adults up to age 60 with acute lymphoblastic leukemia (ALL) is challenging in part due to toxicities of asparaginase as well as myelosuppression. We conducted...
7.
Shah G, DeWolf S, Lee Y, Tamari R, Dahi P, Lavery J, et al.
J Clin Invest
. 2020 Sep;
130(12):6656-6667.
PMID: 32897885
BACKGROUNDUnderstanding outcomes and immunologic characteristics of cellular therapy recipients with SARS-CoV-2 is critical to performing these potentially life-saving therapies in the COVID-19 era. In this study of recipients of allogeneic...
8.
Avecilla S, Goss C, Marionneaux S, Wright D, Leiva T, Tonon J, et al.
Adv Cell Gene Ther
. 2019 Mar;
1(2).
PMID: 30873513
Introduction: CD34+ cell enumeration is a critical parameter used to determine the timing of apheresis collections of hematopoietic progenitor cell products (HPC(A)). Automated hematology analyzers equipped with flow cytometry capabilities...
9.
Chen J, Goss C, Avecilla S, Hong H, Walsh E, Wuest D, et al.
Transfusion
. 2019 Feb;
59(5):1765-1772.
PMID: 30747437
Background: Adoptive immunotherapy using engineered lymphocytes has shown promising results in treating cancers even in patients who have failed other treatments. As the first essential step, the number of peripheral...
10.
Park J, Riviere I, Gonen M, Wang X, Senechal B, Curran K, et al.
N Engl J Med
. 2018 Feb;
378(5):449-459.
PMID: 29385376
Background: CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of...